|gardenboy:> You still watching? Just picked up as one of the top fallers today. A quick and dirty look suggests that they are failing to get traction in commercialization - a high level of cash burn. Losses increased to £3.2 million in 07 or just under 10p per share.
I have been unable to see any major imminent turn round.
Can you help?|
|This company has some remarkable IP in their pipeline.
One to watch in 2008 if they proceed with IPOs.|
|2nd February 2006
Holding (s) in Company
Biofusion plc ("Biofusion" or the "Company") has received notification that The
University of Sheffield (the "University") is interested in 9,333,324 shares in
the Company representing approximately 49.59% of the share capital. The Company
was also notified that the same number of shares have been transferred from the
University's wholly owned subsidiary Sheffield University Enterprise Limited
("SUEL") to the University. These shares were previously held by SUEL as
nominees for the University as disclosed in the Company's AIM admission document dated 28th January 2005.|
|well, they say run your profits :~)
- but it's a lot more than I expected to make in such a short time.|
thanks, good coverage on BBC radio earlier this morning|
|item on ITV lunchtime|
good links gb, cheers!|
|the top performing perpetual income and gwth investment trust...
o/t - could you look at Climate Exchange (CLE) - I have created a new thread,
Hi, sorry you've missed the rise, please excuse my ignorance, but who are pli ?|
|morning gardenboy, have only just noticed your thread. this has been on my secondary watch list but obviously should have been on my primary one as i've managed to miss the big climb in jan! i noticed that pli has been a buyer and are a fan of the manager mark barnet. his occasional dabbles in AIM tend to be successfull.
|oh well, at least we've made the top list !|
|25th January 2006
Lifestyle Choices launches world's first triple hormone ovarian reserve test in
Biofusion plc ("Biofusion") today announces its portfolio company, Lifestyle
Choices Ltd ("Lifestyle Choices"), has launched its new triple hormone ovarian
reserve test, Plan Ahead. Lifestyle Choices believes this test offers the most
accurate hormone based ovarian reserve test available to the public, enabling
women to make more informed decisions about whether to try for a baby sooner
rather than later.
Developed by Professor Bill Ledger, Professor of Obstetrics and Gynaecology at
the University of Sheffield, Plan Ahead measures three hormone levels in the
blood. The first two are the ovarian hormones, Inhibin B and AMH; and the third
is FSH, a pituitary hormone. The result is a predictive assessment of the
number of eggs in the woman's ovaries compared to levels expected for women of
the same age. The test is accurate for up to two years ahead.
The test will initially be available by mail order and costs #179. It is
anticipated that Plan Ahead will be available via pharmacies and private clinics
later in the year.
Lifestyle Choices, which plans to offer a range of products in the female
fertility and menopause markets, was founded by Biofusion in October 2005.
Biofusion owns 50% of the company and provided initial seed financing of #65k,
in the form of a repayable loan, to support the launch of the Plan Ahead.
David Baynes, CEO of Biofusion, said: "Female fertility and the choices women
make about when to start a family attract a great deal of public interest and,
through the work of Professor Ledger, one of the UK's leading fertility experts,
Lifestyle Choices is well positioned to develop products and services to address
this important market. Lifestyle Choices' launch of Plan Ahead also highlights a
number of Biofusion's key strengths: its ability to bring a product or service
quickly to market and the quality of science at the University of Sheffield. In
addition, our portfolio has what we believe is an excellent mix of revenue
generating companies and medium to longer term investment propositions. "|
|The kit is available mail order for £179 but the test has to be done by the women's GP. It only measures the ovarian reserve.
Boots have recently launched a fertility test selling for £89 but that test looks at the quality of the eggs.|
Fertility predictor test launched 25th Jan.
More women are trying for families later in life
Women are being offered a new test kit that allows them to predict the rate at which their fertility is declining.
The test works by measuring the number of eggs in a woman's ovaries and indicating what that level might be like in two years time.
It is hoped the test, designed by fertility experts at Sheffield University, will help women decide how long they can delay trying for a baby.
The Plan Ahead test is only available privately for £179 and not on the NHS.
The reality of modern life is that women in the Western world are putting off starting a family until they are in their thirties
Professor Bill Ledger
Sheffield fertility expert Professor Bill Ledger, who developed the test kit over five years, said he was confident it was an accurate predictor of fertility and that he hoped it would allow women to plan for the future.
"If having family is the most important thing, you're best trying to have babies when you're in your twenties - there's no question that the longer you delay, the bigger your chance of heartbreak," he said.
"But I think the reality of modern life is that women in the Western world, for all sorts of good reasons, are putting off starting a family until they are in their thirties."
He said: "There is more research going on but this is good enough to do what it says it does - give people a two-year warning that their ovarian reserve is declining."
Critics have voiced doubts about the test, pointing out that lack of fertility can have complex causes.
The test measures the levels of three fertility hormones in the blood and plots the results against average fertility for the woman's age.
On the third day of her period, a woman gives a 3ml sample of blood, which is sent off for laboratory testing to measure the levels of the hormones.
Couples would be better off spending their money on a candlelit dinner
Dr Susan Bewley
The first two are Inhibin B and AMH, which decline as the menopause approaches.
The third is a pituitary hormone known as FSH - this tends to increase when the menopause nears.
A combination of the three will indicate the woman's reserve fertility, scientists say.
This is then plotted onto a graph showing the woman's position compared with the average fertility for women of the same age.
The predictive nature of this test means that the woman's ovarian reserve can be predicted for the next two years, says manufacturer Lifestyle Choices which is linked to the University of Sheffield.
Fertility is known to sharply decline from the age of 35, on average, but some women's ability to have children falls even earlier.
One in 100 women have their menopause by the age of 40, but fertility begins to decline a number of years before its onset.
Clare Brown, chief executive of Infertility Network UK, said the test was a good way of allowing women to make a more informed decision about when to try for a family.
But she added: "It is important to realise that whilst Plan Ahead is a valuable test, there are other factors that may cause difficulties in conceiving so it is vital that men and women make sure they are fully informed when making decisions on when to have a family."
Dr Susan Bewley, pregnancy specialist at Guy's and St Thomas' Hospital, recently warned in a British Medical Journal article that women risked heartbreak if they delayed attempting to conceive.
IVF doesn't work for everyone and there are dangers in thinking it can
Dr Allan Pacey, British Fertility Society
She said: "The only reliable test of fertility is actually trying to get pregnant. Test kits are likely to lead to people putting off that process and can give false reassurance.
"Couples would be better off spending their money on a candlelit dinner."
Dr Allan Pacey, secretary of the British Fertility Society, said: "This will be a useful test for those women who want to be able to better plan when they want to have their children.
"However, they should remember that female fertility declines with age and that there are dangers of leaving things too late in life.
"IVF doesn't work for everyone and there are dangers in thinking it can."|
|The University of Sheffield is ranked number one in the UK
for stem cell patents,
|........and even more interesting :~)|
|well I guess if it has, it isn't anyone who uses ADVFN - interesting|
|there was a lot of steady small buying this afternoon - has this been tipped?|
Axordia is a stem cell company with a unique portfolio of cell lines, cell differentiation and cell characterisation technologies. Human embryonic stem cells (HESCs) offer substantial opportunities in the drug discovery and toxicology arenas as well as the potential to cure chronic and degenerative diseases.
Axordia's products will provide a significant asset to improve pharmaceutical company drug discovery in the short term and establish Axordia as a key player in the production of quality assured stem cell therapeutic technologies including cells, assays and proliferating factors. The Axordia business model is designed to fully exploit the commercial potential of the fundamental scientific know-how and related intellectual property in a key centre of excellence
note : In Sept 05 Axordia signed an exclusive agreement with Serologicals Corporation (NASDAQ: SERO)
|20th January BIOFUSION plc
Investment in Axordia
Funding to further advance Axordia's stem cell programmes
Biofusion plc ("Biofusion") today announced an investment of #420,000 in Axordia
Ltd ("Axordia"), one of the UK's leading stem cell research companies and part
of the Biofusion portfolio. The investment, which will be provided as
convertible loan stock, will be in two tranches with #280,000 invested now and a
further #140,000 payable after July 2006. As payment for providing this
facility Biofusion will receive an additional 5% of ordinary shares in Axordia
which will take its total holding to approximately 36%.
Axordia will use the funds to further advance the development of its proprietary
endovascular cell lines, which have potential for use in a variety of
therapeutic settings including transplantation, remodelling of blood vessels and
elsewhere to mitigate the need for immunosuppressant therapies. The company's
development of endovascular cells lines is underpinned by the fact that Axordia
is one of only a few companies in the world able to derive its own human
embryonic stem ("hES") cells.
Axordia will also further strengthen its licensing and partnering activities
around its drug discovery and stem cell tools offerings for the pharmaceutical
David Baynes, CEO of Biofusion, said: "This investment will allow Axordia to
take the development of its lead therapeutic programmes to the next level and to
grow its commercial operation. The investment also highlights the strength of
our business model whereby we are able to provide appropriate funding at crucial
stages in our most promising portfolio companies' development and, in this case,
increase our holding."
Dr V Paul Gerskowitch, CEO of Axordia, said: "Our endovascular cell line
programme is unique and backed by strong IPR. The ability of these cells to
prevent localised immune system activation and create new blood vessels has
promise in the treatment of a range of diseases and we look forward to making
further progress. This investment also validates our three-pronged business
strategy which we believe will provide the company with near, mid and long term
revenues and makes best use of our leading position in human embryonic stem
12 October 2005
Biofusion launches first new spin-out company
Lifestyle Choices to focus on female fertility and menopause
Biofusion plc (AIM:BFN) ("Biofusion" or the "Company") today announced the
creation of its first new spin-out company from its University of Sheffield
pipeline agreement. Lifestyle Choices, a company which will offer a range of
products in the female fertility and menopause markets, expects to launch its
first product in January 2006.
Lifestyle Choices draws on the world-leading research of Professor Bill Ledger,
one of the UK's leading fertility experts. Biofusion owns 50% of the company and
has provided initial seed financing of #65k, in the form of a repayable loan, to
support the launch of the company's first product, which will be in the female
David Baynes, CEO of Biofusion, said:
"There is a huge amount of public interest in the area of female fertility and
specifically around the decisions women make about when to have a family.
Professor Ledger is a leading scientist in this field and has developed a number
of products that will allow women to make better informed choices.
"With a product launch expected early next year, Lifestyle Choices will be
immediately revenue generating and thus is an excellent complement to our
existing portfolio of medium and long term investment propositions. We see this
as the first of a number of new companies that we will be spinning out this
|'Fertility clock' test for women
A test is being launched in January which should be able to predict how many viable eggs a woman has left.
The kit, developed by Professor Bill Ledger, of Sheffield University, is being made by Biofusion Plc.
The test measures levels of three hormones in blood to forecast menopause. Two are produced by the ovaries and go down as menopause nears. The third is released by the brain and increases
|Biofusion was founded in 2002 to commercialise university intellectual property. In January 2005 Biofusion signed a 10 year exclusive agreement with the University of Sheffield to commercialise all the University owned medical IP.
Our partnership with a university works on the simple premise that all parties are more efficient and effective if they are able to concentrate on their core skills so the university focuses on creation, whilst Biofusion focuses on commercialisation. At the point of cross-over we ensure we are completely integrated into the university's technology transfer processes, so that the take up and subsequent commercialisation is both seamless and painless.
As a shareholder in Biofusion the university is rewarded and incentivised to ensure that its vast R&D spend (over £500 million over the next 10 years in the case of Sheffield) is focused on generating world class IP, whilst the academics are rewarded with shareholdings in the subsequent portfolio companies.
Biofusion uses its start-up management skills and funds to commercialise this world class IP through licensing or spin-out companies.
Company website : http://www.biofusion.co.uk/
Axordia website (Biofusion owns 36%) http://www.axordia.com/|